Pennsylvania Medicaid

Does Pennsylvania Medicaid cover Zepbound?

Find your Medicaid card name in Pennsylvania

Quick answer · Weight Loss

Pennsylvania Medicaid does not cover it for weight loss on Medicaid.

  • Medicaid: Not covered. Effective January 1, 2026, drugs containing a GLP-1 receptor agonist are not covered for the treatment of overweight or obesity for MA beneficiaries. The policy states: 'GLP-1 Receptor Agonists are not covered for the treatment of overweight or obesity.'

Last verified June 4, 2026. Policy effective January 1, 2026. Source: mab2025112403.pdf. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What Pennsylvania Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Not covered

Effective January 1, 2026, drugs containing a GLP-1 receptor agonist are not covered for the treatment of overweight or obesity for MA beneficiaries. The policy states: 'GLP-1 Receptor Agonists are not covered for the treatment of overweight or obesity.'

Policy note: Pennsylvania MA explicitly ended coverage of all GLP-1 receptor agonists for overweight/obesity effective January 1, 2026. Class-wide exclusion applies to Zepbound for weight_loss indication.

Policy effective January 1, 2026 · verified June 4, 2026 · source: mab2025112403.pdf

Zepbound for Osa

What Pennsylvania Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

  • BMI of 35 or higher
  • Prior trial of 3 other GLP-1 medications (Ozempic, Wegovy, and Mounjaro)
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher), with a documented trial of PAP therapy

Qualification pathways

You can qualify through any one of these.

Initial approval — Zepbound for moderate-to-severe OSA (non-preferred)

All of:

  • Recent BMI >= 35 kg/m2
  • Diagnosis of moderate to severe OSA confirmed within the last 2 years per most recent consensus treatment guidelines (e.g., AASM ICSD) OR baseline AHI >= 15 events/hour
  • At least one clinical OSA symptom: excessive daytime sleepiness (e.g., ESS >= 10) OR reduced sleep-related quality of life (snoring, nocturnal choking, insomnia, partner sleep disruption, morning headaches, nocturia, etc.)
  • Recent 6-month trial of lifestyle changes and behavioral modifications OR medical reason why immediate treatment is necessary
  • Age-appropriate per FDA labeling, compendia, or peer-reviewed literature
  • No contraindication to the prescribed drug
  • History of therapeutic failure of, OR contraindication to, OR intolerance to the maximum FDA-approved doses of Ozempic (semaglutide), Wegovy (semaglutide), AND Mounjaro (tirzepatide)

Plus any one of:

  • Utilization of PAP with documented adherence (>= 4 hours/night on 70% of nights in a consecutive 30-day period)
  • PAP intolerance despite troubleshooting (mask issues, humidity, claustrophobia) AND: utilization of or intolerance to an oral appliance for OSA

Documentation to bring

  • Recent BMI documentation (>= 35 kg/m2)
  • Documentation of moderate-to-severe OSA diagnosis within last 2 years: per AASM/consensus guidelines OR AHI >= 15 events/hour on sleep study
  • Documentation of at least one OSA clinical symptom: ESS score >= 10 (excessive daytime sleepiness) OR sleep-related quality of life impairment (snoring, nocturnal choking, insomnia, partner disruption, morning headaches, nocturia)
  • PAP adherence documentation: >= 4 hours/night on 70% of nights in a consecutive 30-day period — OR documentation of PAP intolerance with troubleshooting attempts AND utilization of or intolerance to an oral appliance
  • Documentation of 6-month prior trial of lifestyle changes and behavioral modifications OR medical reason for immediate treatment
  • Documentation of therapeutic failure of Ozempic (semaglutide) at max FDA-approved dose, AND Wegovy (semaglutide) at max FDA-approved dose, AND Mounjaro (tirzepatide) at max FDA-approved dose — OR contraindication/intolerance to each (with troubleshooting documentation over >= 1 month if intolerance-based)
  • Documentation of age-appropriateness per FDA labeling, compendia, or peer-reviewed literature
  • Documentation of no contraindication to Zepbound
  • If therapeutic duplication: documentation of intent to transition or medical reason for concomitant use

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight and Renewal (OSA): (1) If on GLP-1 <6 months: documentation of lifestyle changes and behavioral modifications; (2) If on GLP-1 >=6 months AND titration complete AND >=3 consecutive months at max tolerated dose: must show 5% total body weight loss and documentation of dietary changes; (3) If on GLP-1 >=6 months but titration not complete or <3 consecutive months at max tolerated dose: may approve up to 3-month trial extension at max tolerated dose with documentation of dietary changes; (4) PAP adherence or PAP intolerance with oral appliance trial maintained; (5) If on GLP-1 >=1 year: must document improvement in OSA symptoms (e.g., decrease in AHI from baseline, improvement in daytime sleepiness); (6) Step-therapy: therapeutic failure/contraindication/intolerance to max doses of Ozempic, Wegovy, AND Mounjaro. BMI and AHI baseline not re-confirmed at renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Mild OSA excluded (moderate-to-severe only, AHI >= 15)
  • Overweight/obesity treatment indication excluded
  • Saxenda (liraglutide) not covered for any indication

Policy note: Zepbound is non-preferred for OSA. Requires step-through therapeutic failure/contraindication/intolerance to maximum FDA-approved doses of ALL THREE of: Ozempic, Wegovy, AND Mounjaro before Zepbound. OSA diagnosis must be confirmed within last 2 years. PAP adherence is defined as >= 4 hours/night on 70% of nights in a consecutive 30-day period. PAP intolerance pathway requires documentation of troubleshooting strategies (mask issues, humidity, claustrophobia) and then either use of or intolerance to an oral appliance. Renewal at >=6 months requires 5% total body weight loss (if titration complete and >=3 months at max tolerated dose) with dietary change documentation; if not yet at max dose, up to 3-month extension may be approved. At >=1 year, must document OSA symptom improvement (AHI reduction or daytime sleepiness improvement). Approval up to 6 months per cycle unless reviewer specifies otherwise. Prescriptions limited to 1-month supply per fill.

Policy effective January 1, 2026 · verified June 4, 2026 · source: mab2025112403.pdf

Why Zepbound requests get denied by Pennsylvania Medicaid

Based on what this policy asks for. Fix these before the first submission.

  1. Your plan's benefit excludes weight loss medications. A prior authorization cannot override a benefit exclusion — ask about a formulary exception or a different covered pathway.
  2. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  3. BMI not documented in the chart notes (or documented without a baseline weight and date).
  4. Required prior medication trials not documented.
  5. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

If weight loss isn't covered on your plan

Pennsylvania Medicaid has separate Zepbound policies that don't depend on the weight loss benefit:

  • Osa — covered on Medicaid.

Zepbound is also sold directly by Eli Lilly without insurance through LillyDirect.

Frequently asked questions

Does Pennsylvania Medicaid cover Zepbound?
Pennsylvania Medicaid does not cover it for weight loss on Medicaid.
How long does a Zepbound approval last with Pennsylvania Medicaid?
Initial approvals last 6 months, and renewals are granted in 6-month periods.
What does Pennsylvania Medicaid require to renew Zepbound?
At least 5% weight loss from the starting weight and Renewal (OSA): (1) If on GLP-1 <6 months: documentation of lifestyle changes and behavioral modifications; (2) If on GLP-1 >=6 months AND titration complete AND >=3 consecutive months at max tolerated dose: must show 5% total body weight loss and documentation of dietary changes; (3) If on GLP-1 >=6 months but titration not complete or <3 consecutive months at max tolerated dose: may approve up to 3-month trial extension at max tolerated dose with documentation of dietary changes; (4) PAP adherence or PAP intolerance with oral appliance trial maintained; (5) If on GLP-1 >=1 year: must document improvement in OSA symptoms (e.g., decrease in AHI from baseline, improvement in daytime sleepiness); (6) Step-therapy: therapeutic failure/contraindication/intolerance to max doses of Ozempic, Wegovy, AND Mounjaro. BMI and AHI baseline not re-confirmed at renewal.
What if my plan excludes weight loss medications?
Pennsylvania Medicaid has separate Zepbound policies for osa, which are covered on some plan types and don't depend on the weight-loss benefit. Zepbound is also available for cash through LillyDirect.
How current is this information?
This page reflects Pennsylvania Medicaid's written policy as of January 1, 2026, last verified against the source document on June 4, 2026.

Other medications under Pennsylvania Medicaid

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes Pennsylvania Medicaid's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.